Wir sind mit live! Mehr erfahren

uniQure

QURE

Börsenwert 1,51 Mrd. $

21,78 USD

-0,74

3,29 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

21,65

-0,13

0,6 %

1 Tag

-3,29 %

5 Tage

-2,68 %

1 Monat

-48,74 %

3 Monate

-44,66 %

6 Monate

29,57 %

Seit Jahresbeginn

-6,88 %

1 Jahr

-63,69 %

5 Jahre

-22,96 %

10 Jahre

203,34 %

Profil: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Mitarbeiter: 221

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 29,7 %

Neutral 43,2 %

Negativ 27 %

uniQure: The Market Graded The Wrong Exam

uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data met both FDA endpoints, showing 75% slowing of composite and 60% slowing of Total Functional Capacity.

uniQure: The Market Graded The Wrong Exam

uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments

New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices.

uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments

Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.

Cedar Grove Capital Q3 2026 Portfolio Update

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop

NEW YORK--(BUSINESS WIRE)---- $QURE #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE FIRM'S INVESTIGATION]What Happened?On September 29, 2026, uniQure released 48-month data for ongoing Phase I/II studies of AMT-130, the Compan.

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop

Schaeffers Research

10 Stocks With Massive Short Squeeze Potential

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

10 Stocks With Massive Short Squeeze Potential

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired uniQure securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.

UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Zacks Investment Research

uniQure Plunges on Additional Data From Huntington's Disease Study

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.

uniQure Plunges on Additional Data From Huntington's Disease Study

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included cUHDRS & TFC four-year data. cUHDRS at year 4 showed 44% slowing, with a non-significant p=0.144. Per QURE, this may have been due to missing data & “survivor bias” in the external control arm. TFC (total functional capacity) data consistently show >60% slowing of disease progression with statistically significant p-values, albeit nominal ones. TFC is the FDA-aligned confirmatory p3 trial's primary endpoint.

uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

24/7 Wall Street

uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far

uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside.

uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violations.

uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt